聚二磷酸腺苷-核糖聚合酶抑制剂治疗晚期卵巢癌的安全性的系统评价

Systematic review of safety for poly ADP-ribose polymerase inhibitors in the treatment of advanced ovarian cancer

为系统评价聚二磷酸腺苷-核糖聚合酶(poly ADP-ribose polymerase,PARP)抑制剂治疗晚期卵巢癌的安全性,以neoplasm、ovarian cancer、PARP等为关键词检索Pub Med、EMBASE、clinicltrials.gov、Cochrane Library和CNKI等数据库中2017年3月前发表的相关临床随机、对照试验文献,共纳入5篇文献进行分析。分析结果显示,PARP抑制剂治疗组的所有不良事件、恶心、血小板减少、乏力、贫血、呕吐、头痛、头晕和食欲不振的发生率均显著高于对照组,3~4级不良事件中的所有不良事件、血小板减少和贫血的发生率也显著高于对照组。但PARP抑制剂治疗的多数不良事件的严重程度较轻,血小板减少和贫血的严重程度较重,应当予以重视。

In order to evaluate the safety of poly ADP-ribose polymerase（PARP） inhibitors, we used neoplasm, ovarian cancer, PARP as keywords to search for studies published before March, 2017 at Pub Med, EMBASE, clinicltrials.gov, Cochrane Library, CNKI and other database, total five articles were found. The incidence of all adverse events, nausea, thrombocytopenia, weakness, anemia, vomiting, headache, dizziness, and loss of appetite and the incidence of all adverse events, thrombocytopenia and anemia in the 3 ~ 4 grade adverse events were significantly higher in the treatment group of PARP inhibitor than in the control group. However, most of the adverse events occurred in the treatment group of PARP inhibitors were mild though thrombocytopenia and anemia were serious, to which attention should be paid.